{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:36:14Z","timestamp":1793644574471,"version":"4.5.1"},"reference-count":143,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"no funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/19420862.2023.2208697","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T23:35:29Z","timestamp":1683761729000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":32,"title":["Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors"],"prefix":"10.1080","volume":"15","author":[{"given":"Kerry A.","family":"Whalen","sequence":"first","affiliation":[{"name":"Cullinan Oncology, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya","family":"Rakhra","sequence":"additional","affiliation":[{"name":"Cullinan Oncology, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen K.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Cullinan Oncology, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Steinle","sequence":"additional","affiliation":[{"name":"Goethe-University Frankfurt","place":["Frankfurt am Main, Germany"]},{"name":"Frankfurt Cancer Institute","place":["Frankfurt am Main, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Michaelson","sequence":"additional","affiliation":[{"name":"Cullinan Oncology, Inc","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Baeuerle","sequence":"additional","affiliation":[{"name":"Cullinan Oncology, Inc","place":["Cambridge, USA"]},{"name":"Ludwig Maximilians University","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.01.031"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003715"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14993"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.09.007"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713158"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2019.1580693"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.12.980"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00335"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.MR0718-269R"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1581"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-0435-8"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2017.11.008"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1058"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01393"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.44"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049028"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0206-4"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12921"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071777"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00909"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)70060-4"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200003)30:3<787:AID-IMMU787>3.0.CO;2-I"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200101)31:1<233:AID-IMMU233>3.0.CO;2-4"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02156"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0761-3"},{"key":"e_1_3_4_32_1","unstructured":"Innate P. Safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-cell Lymphoma That Express KIR3DL2. 2022. (NCT05321147)."},{"key":"e_1_3_4_33_1","unstructured":"The lymphoma academic research O Innate P. study of lacutamab in peripheral T-cell lymphoma. Study of Lacutamab in Peripheral T-Cell Lymphoma. 2025. (NCT04984837)."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.889.889"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4518"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12455"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903347"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80530-0"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj3286"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1537581"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0062"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02558-z"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1259"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745939"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2206"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.132.2.627"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00464"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301249"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.10.008"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061553"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.07.010"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.913215"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12350"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119616"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.3.754"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040064"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1466767"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0473-8"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508123103"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009483200"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0696"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.01.007"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8648-4_19"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222263110"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2007.04.025"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.20151"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003171"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20996"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-625004"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03124"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004701"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-ct003"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01478-w"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-022-00023-5"},{"key":"e_1_3_4_84_1","volume-title":"GTB-3550 tri-specific killer engager (TriKE\u00ae) for high risk hematological malignancies","author":"Gt Biopharma I","year":"2021","unstructured":"Gt Biopharma I. GTB-3550 tri-specific killer engager (TriKE\u00ae) for high risk hematological malignancies. In: GTB-3550 tri-specific killer engager (TriKE\u00ae) for high risk hematological malignancies. 2021. (NCT03214666)."},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092659"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00550-6"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048953"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128749"},{"key":"e_1_3_4_89_1","article-title":"First-in-human study of sar443579 infusion in male and female participants of at least 12 years of age with relapsed or refractory acute myeloid leukemia (R\/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)","author":"Sanofi","year":"2024","unstructured":"Sanofi. First-in-human study of sar443579 infusion in male and female participants of at least 12 years of age with relapsed or refractory acute myeloid leukemia (R\/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS). First-In-Human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia (R\/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS). 2024. (NCT05086315).","journal-title":"First-In-Human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia (R\/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS)"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163561"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5428.727"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095951"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26097"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00441"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni929"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28609"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.288"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/85321"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni0908-1013"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(03)00320-0"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/87757"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6768"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903789"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12072"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05768"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.8.4098"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01112"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21466"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0076-7"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00314"},{"key":"e_1_3_4_111_1","volume-title":"Celyad oncology provides strategic update","author":"Zelkovic S","year":"2022","unstructured":"Zelkovic S Celyad oncology provides strategic update., Celyad oncology provides strategic update. Company Website: Celyad Oncology. 2022"},{"key":"e_1_3_4_112_1","first-page":"4","volume-title":"Celyad oncology. Celyad oncology provides updates on allogeneic and autologous CAR T programs at 62nd ASH annual meeting and exposition","author":"Zelkovic S","year":"2020","unstructured":"Zelkovic S. Celyad oncology provides updates on allogeneic and autologous CAR T programs at 62nd ASH annual meeting and exposition. In: Celyad oncology. Celyad oncology provides updates on allogeneic and autologous CAR T programs at 62nd ASH annual meeting and exposition. Belgium: Mont-Saint-Guibert; 2020. p. 4."},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00378-7"},{"key":"e_1_3_4_114_1","volume-title":"Study in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome patients to determine the recommended dose of CYAD-02","author":"Celyad Oncology SA","year":"2021","unstructured":"Celyad Oncology SA. Study in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome patients to determine the recommended dose of CYAD-02. In: Study in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome patients to determine the recommended dose of CYAD-02. 2021. (NCT04167696)."},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152413"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.1.14"},{"key":"e_1_3_4_117_1","unstructured":"Nkarta I. NKX101 intravenous allogeneic CAR NK cells in adults with AML or MDSNKX101 Intravenous Allogeneic CAR NK Cells in Adults With AML or MDS. 2023. (NCT04623944)."},{"key":"e_1_3_4_118_1","volume-title":"Nkarta announces positive preliminary dose finding data for two lead engineered natural killer cell programs","author":"Mann G","year":"2022","unstructured":"Mann G. Nkarta announces positive preliminary dose finding data for two lead engineered natural killer cell programs. In: Nkarta announces positive preliminary dose finding data for two lead engineered natural killer cell programs. Company website; 2022."},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab018"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0204"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2021.08.013"},{"key":"e_1_3_4_122_1","volume-title":"Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives","author":"Tartaglia C","year":"2023","unstructured":"Tartaglia C. Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives. In: Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives. Fate Therapeutics Company Website; 2023."},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653081"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000157"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000320"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.01.001"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.787"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0687-9"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-16"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1055993"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.05.026"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00896-0"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0693-y"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0845"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.12688\/openreseurope.13314.2"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0483"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao0505"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04772-4"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.1395"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-3506"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2016.0099"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03038"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0224-2"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0956-8"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2023.2208697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:14:51Z","timestamp":1753258491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2023.2208697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":143,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/19420862.2023.2208697"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2023.2208697","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2208697"}}